Bioventus Insider Trade Sparks 303% Buzz: What Mark Leonard’s Move Means for Investors
Mark Leonard’s 7.2% equity boost at Bioventus signals confidence amid high P/E and FDA‑approval pressure—investors weigh growth potential vs. valuation risk.
4 minutes to read